2.1 Responsibilities of Data and Safety Monitoring Boards
2.2 Responsibilities of the Study Monitoring Committee
2.3 Responsibilities of the Independent Medical Monitor
2.4 Responsibilities of the PI adn IRB
2.5 Responsibilities of the Medical Safety Monitor
This document describes the policies and procedures of the NINDS for monitoring interim data from ongoing clinical trials, including data summarizing study performance and the safety and efficacy of the treatment regimens. The procedures outlined herein are in addition to –and not in lieu of– IRB, OHRP and FDA requirements, and any additional applicable NIH guidelines.
The NINDS requires that each clinical trial it supports, regardless of phase, has data and safety monitoring procedures in place to safeguard the well-being of study participants and to ensure scientific integrity. Monitoring must be performed on a regular basis throughout the participant accrual, treatment, and follow-up periods.
Monitoring activities should be appropriate to the trial phase, participant population, research environment, and degree of risk involved. Although the study PI will include a data and safety monitoring plan in his/her grant application, the level of monitoring required for each study is determined by NINDS staff and communicated to the study PI before the trial begins. No study may begin enrolling participants until the monitoring authority has been put into place and approved the study protocol.
A preliminary monitoring plan must be submitted as part of the Research Plan portion of the grant application for a clinical trial. The plan will be examined as part of the peer review process, and any comments and concerns will be included in an administrative note in the summary statement. NINDS staff will ensure that all concerns are resolved before the study begins enrollment.
In addition to the plans for safety monitoring, the NINDS requires that the protocol when applicable include a section describing the plan for interim analyses [link to protocol template], the timing of the interim analyses relative to study events (e.g., "when 20 participants have completed 6 months of follow-up"), and the exact statistical analyses plans. The NINDS requires that the interim analyses and their effect on alpha be pre-specified. The NINDS also requires that any plans to adapt (e.g., sample size, randomization) be pre-specified and supported by relevant simulations when applicable. Any decision rules (e.g., for stopping or pre-planned adaptation) have to be clearly stated. The interim analysis plans and statistical analysis plans are reviewed by the DSMB and may be modified by the DSMB.
As mentioned earlier, the NINDS may require a higher level of monitoring than is specified in the PI’s preliminary Data and Safety Monitoring Plan. In addition, the plan may be further modified in accordance with the IMM’s, the SMC’s or the DSMB’s requirements, both before the study starts enrollment and possibly mid-study.
NINDS will specify one of the several levels of monitoring:
Each study must have only one monitoring authority.
Data and safety monitoring responsibilities for clinical trials consist of review of the research protocol and ongoing study activities, including review of data quality and completeness, review of fidelity to the study protocol, review of adequacy of participant recruitment and retention, review of adverse events, making recommendations to the NINDS and the study PI concerning trial continuation, modification, or conclusion. More details about the role of a DSMB are presented in Section 3, below.
Studies not monitored by a DSMB may be overseen by a Study Monitoring Committee. SMC members (generally physicians and a statistician) will be appointed by the study PI in consultation with the NINDS and must be independent of the study, but can be from the same institution, unless the NINDS requires otherwise. The NINDS Program Official must approve the SMC membership and the specific monitoring procedures, and may participate in SMC meetings.
An Independent Medical Monitor may be appointed by the study PI to oversee a clinical research project if there is more than minimal risk to the participants, but the study is not sufficiently complex that a DSMB or SMC is necessary. The IMM will be independent of the study and have no real or apparent conflict of interest. The NINDS Program Official must approve of the IMM and specific monitoring procedures she/he will follow. The IMM will operate in a manner similar to that of a SMC/DSMB. At each monitoring interval, the NINDS Program Official will receive notification by the IMM that he/she has reviewed the research protocol and ongoing study activities with emphasis on data integrity, protocol adherence and study participant safety issues. The IMM’s review will focus on AEs and reasons for losses to follow up, raising any concerns or issues with the NINDS and the PI, and recommending to the NINDS and PI the continuation, modification or conclusion of the trial, while protecting the confidentiality of the trial data and the results of monitoring.
The Independent Medical Monitor role is distinct from the role of a Medical Safety Monitor. The MSM role is described below under section 2.5.
When a trial is of minimal risk or even if it is of more than minimal risk but involves only a single site, and if the trial involves only one intervention, the NINDS may determine that the study may be adequately monitored by the study PI and his/her IRB. It is expected that the PI will be actively involved in reviewing the progress of each subject on study and will bring to the attention of the IRB adverse events and unexpected problems that may influence the IRB’s decision to allow the trial to continue, in accordance with the IRB’s policies. In addition, the PI is expected to notify the NINDS Program Official.
Each multi-center clinical trial supported by the NINDS will have an independent MSM, nominated by the study PI before participant enrollment begins and subsequently approved by the NINDS Program Official. The MSM is a physician who is not involved in the study and who has no conflict of interest. The MSM is responsible for ongoing monitoring of reports of SAEs submitted by the clinical centers in real time to ensure good clinical practice and to identify safety concerns quickly. The MSM may suggest protocol modifications to prevent the occurrence of particular AEs, e.g., modifying the protocol to require frequent measurement of laboratory values predictive of the event or to improve expeditious identification of SAEs. To minimize bias, the MSM will usually evaluate SAEs blinded to treatment assignment, unless the DSMB/SMC approves partial or complete unblinding. Specific procedures for MSM activities will necessarily vary from trial to trial. For certain trials, the MSM may serve as a resource to the clinical investigators for advice about management of SAEs but may not be involved in other aspects of the trial. The responsibilities of the MSM are worked out between the Steering Committee and DSMB/SMC in advance of starting the trial.
The MSM will prepare regular reports concerning SAEs (not segregated by treatment group) for submission to the PI, and subsequently to the DSMB and, as appropriate, the FDA and collaborating biopharmaceutical companies or device manufacturers. Typically, such reports will be submitted on a regular basis, to be determined by the DSMB. In the event of unexpected SAEs or an unduly high rate of SAEs, the MSM will promptly contact the PI and the NINDS Program Official and, if applicable, the NINDS DSMB Liaison, who will notify the DSMB Chair. The DSMB/SMC may convene a meeting or teleconference to consider the concerns and plan appropriate action. In the event that the MSM is unavailable for an extended period of time (i.e., extended vacation, sabbatical, illness, etc.) a back-up MSM will be nominated by the study PI and approved by the NINDS Program Official.
An NINDS-appointed DSMB is required for trials which may modify the current standards of treatment or public health policy, result in the licensing of a therapeutic agent or device, or extend approved indications to new groups of patients. A DSMB is mandatory for all Phase 3 clinical trials, and it may be required for some earlier phase trials (e.g., trials that involve multiple sites, pose significant risk to participants, are conducted in vulnerable populations, use certain controversial interventions).
The DSMB will meet regularly in person or by teleconference, typically on a semi-annual basis, to monitor the cumulative safety data during participant follow-up. In no instance should more than 12 months elapse between DSMB reviews of cumulative safety data after the first participant has enrolled. The DSMB will monitor the study according to the guidelines specified in the study protocol and the operating procedures established at the initial meeting, unless the DSMB determines during the course of the trial that modification of the guidelines is in the best interest of the study and its participants.
Except as explicitly authorized by the DSMB, it is critical that study investigators will remain blinded to the interim data because knowledge of emerging trends between treatment arms may influence participant enrollment, management and evaluation, thus compromising the study by introducing bias. The DSMB decides in their first meeting if DSMB members will be unblinded. If the DSMB decides to remain blinded, they should consider assigning one DSMB member, when possible a clinician, to be unblinded to treatment assignment. The unblinded DSMB member may decide to unblind other DSMB members as indicated, and for example based on concerns over SAE imbalances between study groups.
The DSMB is responsible for assuring the NINDS that study participants are not exposed to unnecessary or unreasonable risks and that the study is being conducted according to high scientific and ethical standards. Specifically, the DSMB will:
Advise the NINDS and the study investigators as to whether a protocol should continue as scheduled or undergo a modification due to findings that emerged as a result of the monitoring process.
The NINDS-appointed DSMB has an advisory role to the institute. The voting members may include physicians, laboratory scientists, statisticians, ethicists and patient advocates. Collectively, they will have appropriate expertise in the relevant scientific and safety monitoring areas. The precise number of DSMB members and their areas of expertise will be dictated by the complexity of the study. Study PIs may suggest to the NINDS appropriate individuals to serve on the DSMB.
One member of the DSMB is designated as the DSMB Chair. The DSMB Chair is typically a physician.
To avoid any appearance of conflict of interest, it is critical that DSMB members not be involved in the study, have no vested interest in its outcome, and have no financial ties to any commercial concerns likely to be affected by the study's outcome. If at any time a DSMB member perceives that he/she or another member of the Board has a potential conflict of interest, he/she is obligated to bring the issue to the attention of the full DSMB for open discussion and resolution. The NINDS requires DSMB members to complete a conflict of interest disclosure form and a statement of confidentiality, on an annual basis.
The first DSMB meeting takes place before the study is opened to participant accrual, with the goal of reviewing the study protocol, particularly the specific outcome definitions, the analysis plan, the procedures for recording and reporting SAEs, the monitoring proposal, pre-specified interim analysis plan and decision rules, and pre-specified plans for adaptation and decision rules. The informed consent document/process also will be inspected to ensure that all required elements have been included in language understandable to a typical study participant to be enrolled in the trial. It is possible that the DSMB will recommend modification or clarification of the protocol, especially relating to the monitoring plan. A carefully considered, final monitoring plan is important to establish at the outset, because any subsequent deviation from the pre-specified plan may diminish the scientific integrity and credibility of the study.
During this initial meeting, the DSMB will formulate its operating procedures, including: the DSMB's meeting frequency; the types and formats of reports it will receive from the PI and study statistician; the policy on whether and how the members may be unblinded; what interim data (if any) may be released to the study investigators (e.g., overall event rate); and how minutes will be taken and distributed.
The NINDS DSMB meeting format consists of three sessions: Closed Executive Sessions, Open Sessions, and Optional DSMB Sessions with Program Official. The meeting format, including the number of open and closed sessions, and the participation in these sessions is at the discretion of the DSMB. The DSMB Chair, in conjunction with the NINDS DSMB Liaison, is responsible for the DSMB operations and will set the meeting agenda.
Closed Executive Sessions Only DSMB members and NINDS DSMB Liaison participate in closed executive sessions, to ensure complete objectivity as they discuss outcome results by treatment arm as needed, make decisions, and formulate recommendations regarding the study. The DSMB Chair may request additional participants during this session, e.g. MSM, unblinded study statistician.
Open Sessions: DSMB members, NINDS Staff, study PIs and study statistician(s) attend this session, at which data concerning study conduct and aggregate safety data are discussed.
Optional DSMB Sessions with Program Official: DSMB members, NINDS DSMB Liaison, and NINDS Program Official attend this session. During this session no unblinded data (closed report) will be discussed, but other trial issues, such as recruitment, can be discussed in the absence of the investigators.
The format and reporting requirement of unblinded data should be discussed and agreed upon at the first DSMB meeting. At least 14 days prior to the meeting, the study statistician will prepare study reports using the most recent data and send these to the NINDS DSMB Liaison, who will provide the meeting materials to the DSMB members.
Interim data reports will usually consist of two parts, corresponding to the Open and Closed Sessions of the DSMB meeting. Only the DSMB members will receive copies of the Closed Session report, and at the conclusion of the meeting the statistician or the NINDS representative will collect all copies of the report. The Open Session report will focus on study participant accrual and demographics, data completeness, and other study performance measures, any new information (on the intervention or disease/disorder) that may affect the outcome of the trial, and a list of publications or presentations. All data in the Open Session report will be presented in the aggregate, i.e., not by treatment assignment. The Closed Session report will divide study participants according to cumulative data or coded treatment assignment (e.g., Treatments A vs. B), comparing participant demographics and baseline characteristics, rates of and reasons for treatment discontinuation and loss to follow-up, rates of SAEs and, if an interim efficacy analysis is scheduled, rates of efficacy outcomes (depending on the DSMB operating procedures).
Typically, the principal study investigator will have prepared a report addressing specific concerns he or she anticipates the DSMB will have regarding the conduct of the study. This report should be sent to the NINDS DSMB Liaison for distribution to the DSMB along with the Open Session report. Likewise, the study statistician's report for the Closed Session will usually contain his or her assessment of the progress of the trial, including recommendations on whether it should be terminated or modified. Interim data reports will generally include the following types of information, although only the Closed Session data reports will include comparisons by treatment group. If the randomization is stratified (e.g., by age), these tables and figures are presented by strata:
At the conclusion of each DSMB meeting, the DSMB will provide a verbal report to the principal study investigator indicating areas of concern regarding performance and safety. The DSMB must not communicate any information that could lead to the unblinding of investigators or suggest interim treatment-specific results. Soon thereafter, the DSMB Chair will provide meeting minutes, including the DSMB’s recommendations to the Director of the NINDS Office of Clinical Research, through the NINDS DSMB Liaison. The NINDS OCR Director will determine if the NINDS concurs with the DSMB’s recommendations. The NINDS OCR Director or designee will communicate concurrence or not with the study PI. The NINDS DSMB Liaison will provide the DSMB minutes and recommendations to the study PI, along with a memorandum documenting: (a) the date of the review; (b) that all relevant interim safety and efficacy data were reviewed; (c) recommendations concerning the study execution or modifications to the study protocol; and (d) the anticipated date of the next review. The PI will promptly forward a copy of this memorandum to each participating study investigator for submission to their local IRBs, pursuant to the NIH's Guidance on Reporting Adverse Events to Institutional Review Boards for NIH-Supported Multicenter Clinical Trials (see NOT-99-107).
If the DSMB recommends an amendment to the protocol, it must be approved by the NINDS OCR Director, the IRBs and, for IND or IDE studies, the FDA. NINDS concurrence is required because some decisions may have significant programmatic implications. For example, a decision to extend the duration of a trial or increase the sample size has implications for the NINDS budget.
If as a result of interim data monitoring the DSMB determines that a trial: (a) has answered the primary study question; (b) is futile or will not be able to reach a firm conclusion; (c) cannot recruit participants within a reasonable timeframe (as determined by the NINDS); (d) is not being conducted according to high scientific or ethical standards; or (e) poses an unreasonable or unnecessary risk to study participants, the DSMB will recommend to the NINDS representative that the study protocol be amended, temporarily suspended, or terminated, as appropriate. If the NINDS OCR Director concurs, this recommendation will be conveyed to and discussed with the PI before any action is taken. It will be important to ensure that the PI understands the DSMB's rationale. In addition, prior to a public announcement of a trial's early termination, a plan should be developed and implemented for notifying the study investigators, the IRBs and the study participants. When a study is conducted under an IND or IDE, the FDA and the involved biopharmaceutical companies or device manufacturers must also be notified. A decision to modify or terminate a trial may influence the conduct of another, similar clinical trial and the NINDS may arrange to debrief that trial's study investigators or its DSMB in advance of the public announcement.
The DSMB and PI/study staff should not discuss the study or its progress outside the DSMB scheduled meetings and not without an NINDS DSMB Liaison. The NINDS DSMB Liaison will serve as a conduit for all correspondence between the DSMB and the PI or study staff.
For clinical trials funded in whole or in part by the NINDS and involving an IND or an IDE (regardless of who the official sponsor is), a participating study investigator is obligated to inform the NINDS of any significant communication from the FDA concerning the trial, including warning letters, investigator disqualification notices, clinical holds, etc., within 72 hours of first learning of this FDA communication. Formal notification should be made in writing, but initial notification may be done by telephone if a written notice would delay the notification. It should include a statement of the action taken or contemplated and the assistance needed to resolve the situation. This policy is detailed in the Notice to NIH Grantees/Contractors Regarding Letters or Notices from the Food and Drug Administration (FDA) (see NOT-OD-00-053). The NINDS will bring the matter to the attention of the DSMB.
NIH Policy for Data and Safety Monitoring (NOT-98-084)
Further Guidance on Data and Safety Monitoring for Phase I and Phase II Trials (NOT-OD-00-038)
NIH's Guidance on Reporting Adverse Events to Institutional Review Boards for NIH-Supported Multicenter Clinical Trials (NOT-99-107)
Notice to NIH Grantees/Contractors Regarding Letters or Notices from the Food and Drug Administration (FDA) (NOT-OD-00-053).
NINDS Office of Clinical Research at CRLiaison@ninds.nih.gov
Policy Effective Date: September 14, 2011
Last updated August 8, 2013